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Adaptation of antibody neutralization-resistant human immunodeficiency virus type I (HIV-1) to growth in vitro generally results in the
acquisition of a neutralization-sensitive phenotype, an alteration of viral growth kinetics, and an array of amino acid substitutions associated
with these changes. Here we examine a panel of Env chimeras and mutants derived from these neutralization-resistant and -sensitive parental
Envs. A range of neutralization and infectivity phenotypes was observed. These included a modulation of the CD4 binding site (CD4bs)
towards recognition by neutralizing and non-neutralizing CD4bs-directed antibodies, resulting in a globally neutralization-sensitive Env;
alterations which affected Env complex stability; and interactions which resulted in differential infectivity and CCR5/CXCR4 usage. This
range of properties resulted from the complex interactions of no more than three amino acids found in key Env locations. These data add to a
growing body of evidence that dramatic functional alterations of the native oligomeric Env protein complex can result from relatively minor
amino acid substitutions.
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Introduction Neutralizing monoclonal antibodies (MAbs) have beenThe generation of a broadly neutralizing antibody res-
ponse remains a major goal in the development of a human
immunodeficiency virus type 1 (HIV-1) vaccine, in
addition to other immune effector mechanisms (Garber et
al., 2004; Klausner et al., 2003). However, natural
envelope polymorphisms, poor presentation, and/or immu-
nogenicity of defined neutralizing antibody epitopes, the
potential for Fescape_ from neutralizing antibodies, and
neutralization resistance in general have all greatly
hampered vaccine strategies to date (Burton et al., 2004).0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.03.033
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E-mail address: sib2005@med.cornell.edu (S. Beddows).characterized as interfering with attachment to CD4;
disrupting gp120/CD4/co-receptor interactions; or prevent-
ing fusion with the target cell membrane (Burton et al.,
1994, 2004; Conley et al., 1994; Muster et al., 1993; Thali
et al., 1991a, 1993; Trkola et al., 1996; Zwick et al.,
2001). While antibodies with these specificities are reac-
tive against a diverse range of isolates (Binley et al., 2004;
D’Souza et al., 1997; Trkola et al., 1995), they appear to
be rarely generated during natural infection. Broadly cross-
neutralizing antibodies can be generated during natural
infection, albeit to low titer (Moore et al., 1996; Nyambi et
al., 1996; Weber et al., 1996), but their specificity has
rarely, if ever, been fully defined. Encouragingly, passive
transfer studies using MAbs or polyclonal antisera provide
a proof of principle that pre-existing neutralizing anti-
bodies can significantly protect against HIV/SHIV chal-05) 136 – 148
S. Beddows et al. / Virology 337 (2005) 136–148 137lenge (Conley et al., 1996; Mascola et al., 1999, 2000;
Shibata et al., 1999; Veazey et al., 2003).
In one approach to defining novel neutralizing antibody
epitopes for vaccine exploitation, several groups are trying
to define viral envelope alterations that confer differential
neutralization sensitivity or resistance. Such alterations arise
from passage of laboratory-adapted or clinical HIV-1
isolates in vitro or in vivo, in some cases under antibody
selection pressure. They have been reported to affect
neutralization sensitivity of HIV-1 strains to individual
MAbs or more globally to a range of antibodies directed to
diverse epitopes (Cayabyab et al., 1999; Cheng-Mayer et al.,
1999; Follis et al., 1998; Mo et al., 1997; Park et al., 1998;
Pugach et al., 2004; Reitz et al., 1988; Sawyer et al., 1994;
Watkins et al., 1996; Wrin et al., 1995). While some of these
alterations were found in defined neutralizing antibody
epitopes and affect antibody binding directly, many were
found at distant residues and are presumed to confer
neutralization sensitivity or resistance indirectly, possibly
by changing the overall structure of the HIV-1 envelope.
In a previous study, we described the differential
neutralization sensitivity of a peripheral blood mononuclear
cell (PBMC)-derived R5X4 HIV-1 strain (W61D) and its T-
cell line adapted (TCLA) counterpart to HIV-1-specific
MAbs, HIV-1 patient sera, and envelope-homologous
vaccinee sera, despite the absence of any changes in V1,
V2, and V3 (Beddows et al., 1999). We have now generated
full-length env clones from the PBMC and TCLA virus
stocks, in addition to the construction of 5 chimeras and 10
mutants, to elucidate the mechanisms of this differential
neutralization sensitivity. We demonstrate that the altered
neutralization phenotypes for HIV-1W61D during T-cell line
adaptation are due to conformational changes within the
native Env oligomer rather than alteration of specific
antibody epitopes. Structure–function studies such as these,
especially where co-operativity between Env domains are
implicated, should help to elucidate how neutralization
resistance occurs, and contribute to our understanding of
critical targets for vaccine development.Results
Parental Env variants display a range of neutralization
sensitivities to HIVIg
Wegenerated parental env-gene clones from acutely infec-
ted PBMC (HIV-1W61D/PBMC) and SupT1 (HIV-1W61D/SupT1)
cells using the same virus stocks that have been previously
described to display differential neutralization sensitivities
to a range of anti-Env antibodies (Beddows et al., 1999). In
all, seven full-length functional env-genes were rescued;
four from the HIV-1W61D/PBMC-infected cells (7.1, 7.4,
7.12, and 7.15) and three from HIV-1W61D/SupT1-infected
cells (6.7, 6.14, and 6.24). Env-pseudotyped virus bearing
the encoded Envs were able to infect both CXCR4- andCCR5-expressing U87.CD4 cells, recapitulating the paren-
tal R5X4 biological phenotype (data not shown). In order to
assess whether the parental Env variants also displayed the
differential neutralization sensitivity apparent in the virus
stocks from which they were derived, we first tested Env-
pseudotyped virus stocks against the Ig-purified polyclonal
reagent, HIVIg (Fig. 1). Overall, the SupT1-derived clones
were more neutralization sensitive (P < 0.01; Mann–
Whitney U test) than the PBMC-derived clones, though the
distribution of neutralization titers between the two groups
did overlap. For example, two of the three SupT1-derived
clones (6.7 [mean T SD IC50, 6 T 4 Ag/ml; n = 4] and 6.14
[71 T 8 Ag/ml]) and one PBMC-derived clone (7.15 [137 T
98 Ag/ml]) were relatively neutralization sensitive, while
one PBMC clone (7.12 [923 T 117 Ag/ml]) was particularly
neutralization resistant. Indeed, Env-pseudotyped virus
expressing the envelope from clone 6.7 was 154-fold more
sensitive to neutralization than the pseudovirus derived
from clone 7.12. The remaining three clones (6.24, 7.1, and
7.4) were of intermediate sensitivity, displaying a 2- to 3-
fold greater sensitivity to HIVIg than clone 7.12.
env-gene sequencing analysis
Each parental env-gene clone was fully sequenced and
Env translation products were aligned with the amino acid
sequence of the neutralization resistant clone, 7.12, to allow a
better assessment of what polymorphisms may have
accounted for the observed differential neutralization sensi-
tivity (Fig. 1). One substitution, E440G (numbered according
to the HXB2 Env sequence), was present in 3/3 SupT1 clones
but 0/4 PBMC clones, suggesting it had arisen during T cell
line adaptation. Three changes, D241N, N636D, and K805Q,
were found in all clones except 7.12, suggesting that one or
more of them may modulate neutralization sensitivity in the
remaining Envs. However, the 1–2 log10 increase in neutrali-
zation sensitivity to HIVIg displayed by clones 6.7, 6.14, and
7.15 was unlikely to be due to these polymorphisms alone.
Three of the Env substitutions (N188K, D241N, and N616K)
would be expected to alter potential N-linked (NXS/T)
glycosylation sites. The neutralization-sensitive clone 6.7
had a substitution (D457G) in a position involved in gp120
binding to CD4 (Kwong et al., 1998), a substitution in the V3
domain (A316T), and a substitution in the leucine zipper-
(LZ)-like domain in gp41 (H564N) (Douglas et al., 1997).
This latter substitution was also found in clone 6.24, which
displayed intermediate neutralization sensitivity to HIVIg.
Indeed, all three SupT1-derived clones and the neutralization
sensitive PBMC-derived clone, 7.15, had one or more
substitutions in, or adjacent to, this gp41 domain.
Env glycoprotein determinants of neutralization sensitivity
In an attempt to delineate the impact that one or more of
these amino acid substitutions may have on the overall
neutralization sensitivity of the W61D Env, we initially
Fig. 1. Amino acid sequences of the full-length parental Env clones derived from the PBMC (7.1, 7.4, 7.12, and 7.15) or TCLA (6.7, 6.14, and 6.24) stocks of
W61D and the recombinant chimeric (Ch) and mutant (M) Envs derived thereof. The positions of the restriction enzymes EcoRI, PpuMI, BsiWI, and XhoI are
noted, as are the resulting Env domains contained in the fragments following enzyme digestion. C refers to the indicated gp120 constant domain, AD refers to
the assembly domain of gp41, and AH refers to the amphipathic a-helices (Douglas et al., 1997). Env polymorphisms were numbered according to the residues
in the HIV-1 HXBc2 Env, in line with current convention. All sequences are compared to the neutralization resistant Env clone 7.12, with differences denoted
by a vertical bar at the indicated position. Neutralization values for each Env-pseudotyped virus are presented as the fold increase in neutralization sensitivity as
a function of the mean HIVIg IC50 derived from 2–4 experiments. Note that since the neutralization data generated for the parental Env clones were determined
using a different stock of HIVIg than that for the chimeras or mutants, the derived values presented are relative to parental Env 7.12 (6.7, 6.14, 6.24, 7.1, 7.4,
and 7.15) or chimeric Env Ch2 (Ch5, M1–M10). ND, not done.
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occurring restriction enzyme sites, PpuMI and BsiWI (Fig.
1). We reasoned that the amino acid substitutions present
between the C4 domain of gp120 and the assembly domain
of gp41 found in clones 6.7, 6.14, and 7.15 would most likely
recapitulate these neutralization phenotypes. Indeed, the
chimeric Env-pseudotyped viruses Ch1/Ch2 (7.12), Ch3
(7.15), Ch4 (6.14), and Ch5 (6.7) displayed a neutralization
phenotype almost identical to that of the indicated parental
clone on which they were based, when tested in neutraliza-
tion assays using a polyclonal HIV-1-positive human serum
(data not shown). For example, both the Ch5 chimera and
clone 6.7 (90% neutralizing titer of >320) were substantially
more neutralization sensitive than chimera Ch2 and clone
7.12 (90% neutralizing titer, 10). These data confirmed that
the neutralization phenotype displayed by these two chime-ras, at least against this polyclonal human HIV-1-positive
serum, was conferred by the interaction of no more than the
four amino acid substitutions; E440G, D457G, H564N, and
N636D. The D241N and K805Q substitutions, therefore, did
not appear to impact on the neutralization sensitivity or
resistance of these Env clones.
A more detailed assessment of the neutralization sensi-
tivity or resistance of these two chimeric Env-pseudotyped
viruses, Ch2 and Ch5, suggested these four amino acid
substitutions confer a globally neutralization sensitive
phenotype against a panel of monoclonal and polyclonal
antibodies (Fig. 2). However, while Ch5 was clearly more
neutralization sensitive than Ch2 to a polyclonal serum
preparation (HIVIg; see also Fig. 1), to a V3-specific MAb
(447-52D), to two CD4bs-directed MAbs (F105 and 205-
46-9), and, marginally, to a MAb with a neutralization
S. Beddows et al. / Virology 337 (2005) 136–148 139determinant in gp41 (2F5), this was not the case for the
gp120-specific MAb 2G12 (which recognizes a unique
mannose-dependent epitope), nor for two other CD4bs-
directed reagents (CD4-IgG2 and b12).
To further define the interaction of these four amino acid
substitutions, we constructed a panel of 10 mutant Envs
(designated M1–M10). In these mutants, we used site-
specific mutagenesis to introduce each substitution individ-Fig. 2. Neutralization sensitivity of Ch2 (filled circles) and Ch5 (open circle
neutralization reagents: A, HIVIg; B, 2G12; C, 2F5; D, 447-52D; E, CD4-IgG2
U87.CD4.CXCR4 cells in the presence of increasing amounts of the indicated antib
Fig. 3. Data are representative of two experiments.ually, or in combination, into the Ch2 background (Fig. 1).
Two of the parental clones (6.7 and 7.12), the chimeras Ch2
and Ch5, and the mutant Envs (M1–M10) were then tested
against a single concentration of anti-Env antibody prepa-
ration in neutralization assays (Fig. 3). While this approach
is useful for screening large numbers of (pseudo)viruses and
antibodies (Si et al., 2001), we do recognize the limitations
of testing for neutralization efficacy using a single concen-s) chimeric, Env-pseudotyped HIV-1 stocks by a panel of Env-specific
; F, b12; G, F105; H, 205-46-9. Inhibition of infection was performed on
ody (Ag/ml, x-axis). The arrow indicates the antibody concentration used in
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isons where there is <2-fold difference to be significant by
this method.
The neutralization sensitivity profiles of the chimeric
Envs, Ch2 and Ch5, to these monoclonal and polyclonal
Env-specific reagents (Fig. 2), were effectively represented
using the single concentration of neutralizing reagent in thisFig. 3. Neutralization sensitivity of parental (6.7 and 7.12), chimeric (Ch2 and Ch5
Env-specific antibodies: A, HIVIg; B, 2G12; C, 2F5; D, 447-52D; E, CD4-IgG2;
was 100 Ag/ml, and 0.5 Ag/ml for the monospecific reagents. Bars represent the m
for the parental and mutant Envs against 447-52D, which represent the mean ofassay format (Fig. 3). The mutant viruses containing the
individual changes E440G (M1), H564N (M3), and N636D
(M8) were marginally more neutralization sensitive to HIVIg
than Ch2 (Fig. 3). The E440G/H564N (M5) double mutant
and the E440G/H564N/N636D (M10) triple mutant dis-
played greater neutralization sensitivity to HIVIg, relative to
Ch2. Indeed, the marginal increases in sensitivity seen with), and mutant (M1–M10) Env-pseudotyped HIV-1 stocks against a panel of
F, b12; G, F105; H, 205-46-9. The concentration used for polyclonal HIVIg
ean (TSD) percentage neutralization derived from three experiments, except
two experiments.
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greater neutralization sensitivity displayed by M5 and M10
Envs, are consistent for most of the antibodies used.
Env-pseudotyped viruses containing the D457G muta-
tion (6.7, Ch5, M2, M4, M6, M7, and M9) were also more
sensitive to HIVIg, 2F5, and 447-52D neutralization than
Ch2. Envs containing this mutation were markedly resistant
to b12 and CD4-IgG2, while their sensitivity to F105 and
205-46-9 was unaffected or even enhanced, relative to
mutants lacking this substitution. Comparisons of M5 with
M7 and Ch5 and M10 highlight the differential effects of the
D457G mutation on recognition of the CD4bs by these
CD4bs-directed reagents.
To extend these observations, we tested the sensitivity
of the chimeric Envs Ch2 and Ch5, and mutant Env-
pseudotyped viruses (M1–M10), to HIVIg and two CD4bs-
directed reagents, 205-46-9 and CD4-IgG2, in a more
traditional assay in which the antibodies were titrated
against input pseudovirus (Table 1 and Fig. 1). This
confirms the minor increase in neutralization sensitivity to
all three reagents conferred by the individual mutations
E440G (M1; a 6.7-fold increase in sensitivity to HIVIg over
that obtained for Ch2) and H564N (M3; 9.7-fold), the at
least additive effect displayed by the double mutant E440G/
H564N (M5; 291-fold), and the lack of an apparent effect of
the N636D (M8; 1.1-fold) mutation. These data also
confirm the differential effect of the D457G mutation on
sensitivity to antibodies directed against the CD4 binding
site on gp120. There were, however, some minor discrep-
ancies between the two assay systems. For example, M8
Env-pseudotyped virus appeared to be more sensitive than
Ch2, and marginally less sensitive than M1, to neutraliza-
tion by HIVIg in the single concentration assay (Fig. 3). In
the more robust assay system using a serial dilution of
antibody, the M8 Env-pseudotyped virus was essentially as
resistant as Ch2, and M1 was 6-fold more sensitive to this
reagent (Table 1 and Fig. 1). Thus, the single concentrationTable 1
Neutralization of pseudotyped HIV-1W61D bearing chimeric and mutant Envs
a
Env Polymorphisms HIVIg
50% 90%
Ch2 87.5 (25) >100
Ch5 E440G/D457G/H564N/N636D 0.8 (0.8) 3.9 (2.8
M1 E440G 13 >100
M2 D457G 2.4 18
M3 H564N 9 >100
M4 E440G/D457G 0.6 20
M5 E440G/H564N 0.3 0.7
M6 D457G/H564N 0.8 13
M7 E440G/D457G/H564N 0.5 8.3
M8 N636D 83 >100
M9 E440G/D457G/N636D 0.8 10
M10 E440G/H564N/N636D 1.3 13
a Numbers indicate mean (SD) of 4 determinations for Env-pseudotypes Ch2 and C
in Ag/ml for each neutralizing reagent at the indicated neutralization endpoint (50neutralization assay was used to generalize on patterns of
reactivity only, and more weight should be applied to
neutralization data derived using the antibody dilution assay.
Antigenicity assessment of W61D Envs
To determine whether the differential neutralization
sensitivity of the Env clones was due to sequence poly-
morphisms within the epitopes of the antibodies, or an
indirect effect on exposure of these epitopes on the native
Env oligomer, we assessed the ability of these antibodies to
bind monomeric gp120 derived from lysed Env-pseudo-
typed virion preparations. The binding of polyclonal HIVIg
or the CD4bs-directed MAbs, 205-46-9 and F105, to these
Env-pseudotyped-derived gp120s in an ELISA was unaf-
fected by any of these amino acid substitutions (Figs. 4A
and B, and data not shown). In contrast, the binding of the
CD4-IgG2 reagent and MAb b12 towards any gp120 that
contained the D457G mutation (6.7, Ch5, M2, M4, M6, M7,
and M9) was severely disrupted (Fig. 4C, and data not
shown). A similar result was obtained using soluble
monomeric gp120 proteins expressed in vitro, rather than
derived from lysed pseudovirions (data not shown). The
limitations of a gp120-based assay system notwithstanding,
these results suggest that of the possible gp120 poly-
morphisms found within these Envs, only the D457G
mutation directly modifies the binding site for any of the
test reagents. Hence neutralization sensitivity to these
reagents must be conferred indirectly, for example, by
alteration of the exposure of gp120 epitopes by a
combination of gp120 and gp41 sequence changes.
Relationship between infectivity and neutralization
sensitivity
During the course of these studies, it was apparent that
when the stocks were titrated on susceptible co-receptorCD4IgG2 205-46-9
50% 90% 50% 90%
0.22 (0.11) >1 >1 >1
) 0.76 (0.48) >1 0.02 (0.01) 0.11 (0.01)
0.05 1 0.1 >1
>1 >1 0.07 >1
0.3 0.9 0.11 >1
>1 >1 0.008 0.2
0.04 0.5 0.02 0.2
>1 >1 0.001 0.06
>1 >1 0.03 0.6
0.25 >1 >1 >1
>1 >1 0.08 0.8
0.01 0.3 0.05 0.2
h5, or representative data from two experiments for the mutants M1–M10,
% or 90%).
Fig. 4. Antibody binding to Env-pseudotyped virus-derived gp120 by
ELISA. The indicated concentrations of (A) HIVIg, (B) 205-46-9, and (C)
CD4-IgG2 were allowed to bind to solubilized pseudovirion-derived gp120
before being resolved with anti-human conjugated antibody. Data are
representative of that derived from several experiments.
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luciferase activity than clone 7.12 or Ch2, although for
neutralization studies the amount of input virus was
normalized by luciferase output to reflect this disparity. A
relationship between high infectivity and neutralization
resistance has previously been demonstrated (Leavitt et
al., 2003; Park and Quinnan, 1999). Hence we wished to
assess any possible similar relationship with our recombi-
nant Envs. To do so, supernatant from Env-pseudotyped
Ch2 and Ch5 chimeras, and all 10 mutants, were titrated on
U87.CD4.CXCR4 cells and the luciferase content deter-
mined after 3–4 days. Chimeric or mutant Env-pseudotyped
viruses containing the E440G, D457G, or H564N mutations
were 20- to 481-fold less infectious than the Ch2 chimericEnv-pseudotyped virus, suggesting that these mutations
alone or in combination impaired the ability of virus to bind
or enter susceptible target cells (Fig. 5A). Env-pseudotyped
viruses containing both the E440G and D457G mutations,
M4 and M9, were the least infectious, being 316-fold and
481-fold less infectious than Ch2, respectively. The N636D
mutation (M8) displayed similar infectivity to that observed
with Ch2. There was a significant correlation between the
infectivity (TCID50) of the Env-pseudotyped virus stocks
generated by transient transfection of 293T cells and the
resultant neutralization sensitivity of these Env-pseudotyped
virus stocks to the polyclonal reagent, HIVIg (Spear-
mans Rank Correlation, P < 0.01). However, as the Env-
pseudotyped virus stocks were normalized to approximately
the same level of infectivity for the neutralization assay, and
neutralization by a polyclonal reagent such as HIVIg is
likely to be mediated by antibodies with varying affinities
for each Env, such a simplistic association should be treated
with some caution.
It was possible that the differences in infectivity noted here
were simply due to a reduced output of Env-pseudotyped
virus; thus, we attempted to relate Env-pseudotype infectivity
as a function of pseudovirion particle output (p24 content). To
do so, we first had to separate virions from free p24 that
would confound such measurements. However, when the
various supernatants were concentrated through a sucrose
cushion and tested against CXCR4-bearing cells, only some
of the chimeras and mutants generated the expected (given
the volume adjustments) 10-fold increase in luciferase
output. Indeed, chimera Ch2 and all other mutants that
lacked the H564Nmutation (M1,M2,M4,M8, andM9) were
less infectious after purification; their luciferase output was
reduced by 1–2 log10 (18- to 447-fold reduction; Fig. 5B).
This was an unexpected finding, since sucrose cushion
centrifugation does not affect HXB2 or JR-FL Env-
pseudotyped HIV-1 in this way (data not shown). The
reduction in infectivity was not due to a reduced recovery of
virus particles, because p24 antigen and RT content of the
various sucrose-pelleted samples were similar (data not
shown). Also, the Env and Gag contents of sucrose cushion-
concentrated Ch2 and Ch5 Env-pseudotyped HIV-1 were
seemingly unaffected by sucrose cushioning, as assessed by
Western blotting (data not shown). In addition, determina-
tion of Env-pseudotyped virus spike density following
S1000 column separation of virions from soluble proteins
(O’Brien et al., 1994) suggested that the Ch2 and Ch5
chimeric Env-pseudotype viruses contained similar amounts
of gp120 (data not shown).
The simplest explanation of these seemingly contra-
dictory observations is that the Ch2 chimeric fusion-
competent Env spikes are somehow functionally impaired
by ultracentrifugation (but not by S-1000 chromatography, a
gentler technique). One way to test this possibility was to
assess whether Ch2 sheds gp120 more readily than the Ch5
chimera. When we assessed the gp120 content of the test
viruses, we found that sucrose-pelleted Ch2 chimeric Env-
Fig. 5. Relative impact of Env polymorphisms on Env-pseudotyped virus infectivity. Culture supernatant containing Env-pseudotyped HIV-1 was
generated by transient transfection of HEK 293T cells and relative infectivity was determined. (A) TCID50 measurements of untreated supernatant were
normalized against those obtained for chimera Ch2 and represent the mean of two such determinations. (B) Relative infectivity, using luciferase RLU,
was determined for each Env-pseudotyped virus prior to and following concentration through a 20% sucrose cushion and represent the mean (TSD) of
data derived from 2–3 experiments.
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without sCD4 shed ¨3–4 times more gp120 than the
similarly treated Ch5 chimera (data not shown). Thus, at
least one potential explanation of this phenomenon appeared
to be gp120 instability on the Env-pseudotyped virus.
All these clones, chimeras, and mutants could utilize
either CXCR4 or CCR5 for entry, although there were
minor differences in the efficiency of co-receptor usage
for mutants that did not contain the H564N mutation. The
latter mutant Env-pseudotyped viruses replicated on
U87.CD4.CXCR4 cells approximately twice as efficiently
(mean 1.92, SD 0.48) as on U87.CD4.CCR5 cells, while
Ch5 and mutants containing the H564N mutation replicated
on U87.CD4.CXCR4 cells less efficiently than on
U87.CD4.CCR5 cells (mean 0.88, SD 0.33) (data not
shown).
The above studies suggest that any relationship between
infectivity and neutralization sensitivity of these Env clones
is likely to be complex and influenced by multiple factors.
The infectivity profiles of mutants containing or lacking the
H564N mutation suggest a further role for this change in
modulating pseudovirion infectivity, perhaps by stabiliza-tion of the pseudovirion-associated Env complex, as judged
by the gp120 shedding experiments.Discussion
While cellular adaptation and a concomitant increase in
neutralization sensitivity are not novel phenomena, the
mechanisms by which HIV-1 can adapt to its surround-
ings often involve dramatic structural re-arrangements
within the Env complex. The interplay of these changes
on the associated viral phenotype is worthy of investi-
gation. In this study, we attempted to determine the im-
pact of Env amino acid polymorphisms on the differential
neutralization sensitivity of a PBMC-derived HIV-1 strain
(HIV-1W61D/PBMC) and its T-cell line adapted counterpart
(HIV-1W61D/SupT1) (Beddows et al., 1999). To this end,
we generated seven functional full-length Env clones, five
chimeric Envs, and a panel of ten mutant Envs, then
studied their neutralization sensitivity to polyclonal and
monoclonal Env-specific reagents, Env stability, and their
infectivity as Env-pseudotyped viruses. Diverse infectivity
S. Beddows et al. / Virology 337 (2005) 136–148144and neutralization phenotypes were conferred by the
interactions of no more than three amino acid substitu-
tions (E440G, D457G, and H564N).
In addition to these major substitutions, additional se-
quence changes may have played a minor role in
influencing the neutralization sensitivity of some individual
clones with intermediate neutralization sensitivity. One
substitution, N188K, present in clones 7.1 and 7.4, disrupts
the same potential N-linked glycosylation site as one of
those reported to arise in a CD4-independent Env clone
derived from HXBc2 (LaBranche et al., 1999). The
D589G substitution (clone 6.24) was at one of the
positions reported to affect membrane fusion and virus
infectivity (Cao et al., 1993), and the N616K (clone 6.14)
substitution would be predicted to disrupt another potential
N-linked glycosylation site. The effect of these substitu-
tions is unclear, and we did not directly test them. Of the
three other mutations, one, D241N, also affected a
potential N-linked glycosylation site. The N636D and
K805Q mutations were present in all Envs except the most
neutralization-resistant ones. A logical assumption was that
these two changes might have a significant influence on
neutralization sensitivity. However, we could find no
experimental evidence to support this supposition; the
changes may be inconsequential, or they might have a
minor, undetectable effect.
One substitution, E440G, appeared to be associated with
adaptation on cell lines, in that it was present in all SupT1
clones but none of the PBMC clones. Substitutions at or
near this position have been reported to reduce HIV-1YU-2
gp120 binding to CCR5, reduce Env-pseudotype infectivity
via CCR5, and modulate sensitivity to entry inhibitors,
although neutralization sensitivity to antibodies was not
tested (Reeves et al., 2004; Rizzuto et al., 1998). In the
present study, the E440G mutation reduced infectivity to
both CXCR4- and CCR5-mediated entry and bestowed a
modest increase in sensitivity to Env-specific antibodies.
Another substitution, D457G, which had a significant
impact on virus infectivity and neutralization sensitivity was
located in a position involved in binding of gp120 to CD4
(Kwong et al., 1998). Consistent with its location, this
change impaired the gp120–CD4 interaction at the level of
monomeric gp120. Substitutions at this position have also
been reported to affect the binding of the neutralizing
antibody b12, but not the non-neutralizing b6 antibody, to
gp120 (Pantophlet et al., 2003; Roben et al., 1994). In
keeping with these observations, the neutralization sensi-
tivity and gp120 binding profiles of the D457G-containing
mutants toward CD4bs-directed reagents differed depending
on whether those reagents are considered to be able to
neutralize primary HIV-1 isolates (CD4-IgG2 and b12) or
not (F105 and 205-46-9) (D’Souza et al., 1997; Moore et al.,
1995). Thus, our data confirm that this single amino acid
substitution can modulate the interaction of the CD4 binding
site with such neutralizing and non-neutralizing antibodies
to different extents.The third mutation that we focussed on, H564N, is
located in the LZ-like domain of gp41. It was present in
two SupT1-derived clones (6.7 and 6.24), while a third
TCLA clone (6.14) and one of the neutralization-sensitive
PBMC-derived Envs (7.15) also had changes in the same
general area of gp41. Mutations in this region have been
reported to significantly affect membrane fusion and viral
infectivity, especially substitutions disrupting the leucine/
isoleucine/valine heptad repeat motif characteristic of the
LZ-like domain (Cao et al., 1993; Chen et al., 1993;
Dubay et al., 1992; Sanders et al., 2002; Wild et al., 1994).
While these residues are not thought to greatly affect Env
synthesis, production, or oligomerization, mutations at
adjacent residues have been reported to affect gp41–
gp120 association and Env processing (Cao et al., 1993).
In addition, this mutation is at the same position as one
reported to arise in a HIV-1MN clone that escaped a
neutralizing HIV-1-positive serum, though notably in the
reverse orientation (Asn to His) (Park and Quinnan, 1999;
Park et al., 1998, 2000). That the Asn to His mutation
arose as a result of neutralizing antibody selection pressure
against a TCLA strain (MN), whereas the converse His to
Asn change emerged during T-cell line adaptation of a
resistant primary virus-like Env is intriguing. Envelope
alterations following neutralizing antibody selection and
cellular adaptation may therefore be intrinsically linked.
While Park et al. noted that this mutation did not appear to
have a great impact by itself, it was reported to greatly
modulate the effects of other substitutions (Park and
Quinnan, 1999; Park et al., 1998, 2000). Similarly, co-
operativity between changes in the CD4bs and gp41, and
the impact that these have on the sensitivity of HIV-1LAI to
the small molecule entry inhibitor, BMS-378806, have
recently been demonstrated (Lin et al., 2003).
These findings confirm and extend observations that
relatively few amino acid substitutions in key locations can
have a profound effect on Env function, including Env-
pseudotype infectivity and sensitivity to antibody-mediated
neutralization (Cayabyab et al., 1999; Follis et al., 1998; Mo
et al., 1997; Park and Quinnan, 1999; Park et al., 1998,
2000; Reitz et al., 1988; Sawyer et al., 1994; Watkins et al.,
1996; Wrin et al., 1995). Indeed, the combination of the
CCR5 binding site mutation (E440G) and the gp41 mutation
(H564N) led to a 1–2 log10 increase in neutralization
sensitivity and a decrease in relative infectivity, but without
a detrimental impact on Env complex stability. The latter is
most likely due to the compensatory effect of the H564N
mutation. The inter-relationship between a reduced ability to
bind CD4, a decrease in Env-pseudotype infectivity, and an
increase in neutralization sensitivity, is exemplified by the
partial destruction of the CD4bs by the D457G mutation and
the differential binding and neutralization that this mutation
confers. One possible explanation of this phenomenon
would be that a reduced affinity for CD4 slows the kinetics
of viral entry sufficiently to allow neutralizing antibodies
more time to bind the functional Env complex and thus tip
S. Beddows et al. / Virology 337 (2005) 136–148 145the balance towards neutralization and away from infection.
A reduction of CCR5 affinity and increased sensitivity to
small molecule entry inhibitors has recently been demon-
strated for mutants of HIV-1YU-2 (Reeves et al., 2004). Also,
the apparent instability of the Env complex on the high
infectivity, neutralization-resistant Env Ch2-containing
pseudovirus might reflect the presence of an altered Env
conformation that fuses more rapidly and has a correspond-
ingly reduced susceptibility to neutralizing antibodies. The
extra instability of the envelope may be a problem for the
virus under certain in vivo conditions, or when the virus is
subjected to centrifugation in vitro, but perhaps not under
normal cell culture conditions.
Structure–function relationships such as those described
here should help to elucidate mechanisms of antibody
neutralization resistance and could contribute to our under-
standing of critical targets for HIV-1 vaccine development
and/or the design of small molecule inhibitors of infection.Materials and methods
Construction of env clones, chimeras, and mutants
Full-length (gp160) proviral DNA env sequences were
amplified from crude nuclear extracts from acutely infected
PBMC (HIV-1W61D/PBMC) or SupT1 (HIV-1W61D/SupT1) cells
(Beddows et al., 1999) using nested PCR primers (Connor et
al., 1996), and ligated into the mammalian expression
plasmid pcDNA3.1zeo(+) (Invitrogen) using EcoRI and
XhoI restriction enzymes. These engineered enzyme sites
(EcoRI and XhoI) and the naturally occurring sites within
these clones (PpuMI and BsiWI) were utilized to generate
the chimeric envs (Ch1 to Ch5; see Fig. 1) using standard
cloning methodologies. The Env mutants (M1–M10; see
Fig. 1) were made by site-directed mutagenesis (Stratagene).
A stop codon was introduced into position R511* to create
the gp120-expressing construct. All Env amino acid posi-
tions were numbered according to the residues in the HIV-1
HXBc2 Env, in line with current convention.
Cells and antibodies
The culture conditions for the HEK 293T, U87.
CD4.CCR5, and U87.CD4.CXCR4 cell lines have been
described previously (Gordon et al., 1999). All cell cultures
were maintained at 37 -C in an atmosphere containing
5% CO2. The epitopes for the anti-HIV antibodies used in
this study have been described elsewhere. These include
the CD4 binding site-directed MAbs F105 (Thali et al.,
1991b), 205-46-9 (formally HT7) (Fouts et al., 1997), and
b12 (Burton et al., 1994), the CD4-immunoglobulin G2
(CD4-IgG2) molecule (Trkola et al., 1995), the V3-specific
MAb 447-52D (Gorny et al., 1992), the complex carbohy-
drate-dependent gp120-specific MAb 2G12 (Trkola et al.,
1996), and the gp41-specific MAb 2F5 (Muster et al.,1994). HIVIg was obtained from the AIDS Research and
Reference Reagent Program, Division of AIDS, NIAID,
NIH.
Env-pseudotyped virus infectivity and neutralization assays
Pseudotyped virus stocks were produced by calcium
phosphate (Promega) co-transfection of 293T cells with
each individual pcDNA3.1zeo(+)Env(+) plasmid and the
pNL4-3.LUC.RE reporter plasmid (Connor et al., 1996).
Supernatants were clarified by centrifugation and stored in
aliquots at 80 -C.
For infectivity assays, Env-pseudotyped virus stocks
were serially diluted against U87.CD4.CXCR4 or U87.
CD4.CCR5 cells seeded in 48-well trays at a density of 1 
104/well. Following 3- to 4-day incubation at 37 -C,
monolayers were washed with phosphate-buffered saline,
lysed in cell culture luciferase lysis buffer, and luciferase
activity determined using commercially available reagents
(Promega). Env-pseudotyped virus infectivity was deter-
mined using the Spearman–Karber estimation of TCID50.
For neutralization assays, Env-pseudotyped virus
stocks were normalized to give similar infectious titers
against U87.CD4.CXCR4 cells and pre-incubated for 1 h at
37 -C with various anti-Env antibodies, after which time
this virus antibody mixture was added to monolayers of
U87.CD4.CXCR4 cells. Target cell luciferase activity was
assessed 3–4 days post-infection, as above. Neutralizing
activity for test wells was determined with reference to
control wells containing virus and cells only. In some cases,
a specific antibody titer was determined by interpolation
using a 50% or 90% neutralization endpoint. As all seven
clones were able to use CXCR4 and CCR5 for entry into
susceptible target cells, neutralization studies were per-
formed on the same cells throughout; in this case
U87.CD4.CXCR4 cells. Several previous studies have
demonstrated that antibody-mediated neutralization sensi-
tivity is not affected by specific co-receptor utilization for
dual tropic Envs (LaCasse et al., 1998; Montefiori et al.,
1998; Trkola et al., 1998).
Antibody binding assay to monomeric gp120
The ability of anti-Env antibodies to bind to solubilized
monomeric gp120 prepared from Env-pseudotyped virus
stocks lysed with 1% NP40 was performed essentially as
described (Trkola et al., 1995), with the exception that
pseudovirus stocks were first passed through 0.2-Am filters
and pelleted through a 20% sucrose cushion at approx-
imately 100,000  g (Sw41Ti rotor; Beckman) for 1.5 h at
4 -C to remove soluble gp120.
Western blotting
In order to determine the level of Env and Gag
expression, pseudovirion-containing supernatant was clari-
S. Beddows et al. / Virology 337 (2005) 136–148146fied by filtration through a 0.2-Am filter, then subjected to
centrifugation through a 20% sucrose cushion, as described
above. The pellet was lysed in SDS-sample buffer contain-
ing 100 mM dithiothreitol (Invitrogen), boiled for 3 min,
then fractionated on an 8–16% gradient Tris–Glycine gel
(Invitrogen), and transferred to a PVDF membrane using
standard methodologies. The membranes were subsequently
blotted with 2F5 (gp41/gp160) or D7320 (p24; Cliniqa
Corp.) antibodies.
Nucleotide sequence accession numbers
The full-length env sequence of the parental PBMC
clone, W61D 7.12, has been deposited with GenBank
(accession number AY973156).Acknowledgments
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